Gilead demonstrates the impact of global collaboration in advancing HIV research and health equity at EACS 2023

Gilead Sciences Inc announced on 16 Oct 2023 its upcoming participation in the 19th European AIDS Conference (EACS) to be held in Warsaw, Poland on 18-21 Oct 2023. As a leader in HIV innovation, Gilead will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development programmes. The research that will be presented at EACS 2023, along with symposia led by Gilead, reflects the company's person-centred approach to advancing scientific innovation and underscores its focus on community partnership to help end the HIV epidemic. At EACS 2023, Gilead will present new findings on long-acting HIV treatment strategies, including outcomes from multiple studies evaluating twice-yearly lenacapavir, Gilead's first-in-class, long-acting HIV-1 capsid inhibitor. These findings will include insights, experience and perspectives from healthcare professionals and study coordinators from CAPELLA, an ongoing Phase 2/3 registrational study designed to evaluate the antiviral activity and safety of twice-yearly lenacapavir administered as a subcutaneous injection in adults with multi-drug resistant HIV who are heavily treatment experienced. Additional lenacapavir data presented at EACS 2023 will provide insight into the therapy's resistance profile. Lenacapavir has exhibited no overlapping resistance in vitro with any currently approved antiretroviral therapy. Original source: Gilead, website: http://www.gilead.com/, Copyright Gilead 2023.
joint venture; research and development; anti-HIV drugs; lenacapavir; Gilead [...]